Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by George Bondi on May 20th, 2026

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $32.2727.

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus raised their target price on shares of Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Wedbush lifted their price target on shares of Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Jefferies Financial Group cut shares of Tango Therapeutics from a “buy” rating to a “hold” rating and lifted their target price for the company from $18.00 to $27.00 in a research note on Thursday, May 14th. Wall Street Zen cut shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings upgraded shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th.

Get Our Latest Analysis on TNGX

Tango Therapeutics Trading Down 1.6%

Shares of TNGX stock opened at $20.30 on Wednesday. Tango Therapeutics has a 12-month low of $1.72 and a 12-month high of $28.41. The firm’s 50 day moving average is $21.72 and its 200 day moving average is $14.46. The stock has a market capitalization of $2.94 billion, a P/E ratio of -24.46 and a beta of 1.22.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. As a group, equities analysts predict that Tango Therapeutics will post -1.34 earnings per share for the current year.

Insider Buying and Selling at Tango Therapeutics

In related news, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the transaction, the insider owned 132,873 shares in the company, valued at approximately $1,696,788.21. The trade was a 29.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 179,056 shares of company stock worth $3,346,181. 6.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at $35,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after acquiring an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in Tango Therapeutics in the 4th quarter valued at $40,000. State of Wyoming bought a new stake in Tango Therapeutics in the 1st quarter valued at $128,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after acquiring an additional 2,243 shares during the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.